EXHIBIT 2

14 February 2024

Ambassador Mr. Xie Feng
Embassy of the People's Republic of China
3505 International Place, N.W.
Washington, D.C. 20008
202-495-2266

Mrs. Jummai Nache and her Family :

Current Medical Status, Post Employer Mandated Pfizer modRNA Injections

Thirteen Pages + Two Pages

Subject : **Mrs. Jummai Nache and her Family**

Current Medical Status Post Employer Mandated Pfizer modRNA Injections

Mrs. Jummai Nache and devoted husband Philip; learning how to walk stairs on prosthetic limbs. Amputation of her limbs caused by modRNA injection mandated by her former employer, the University of Minnesota (UMinn).

A non-smoker, a non-drinker, a *"model of health"* prior to Pfizer needle; amputations in pictorial review caused by modRNA-induced venous and arterial thromboembolism. Such was not merely foreseeable but a known *"mRNA"* danger, discussed in-detail at the secret FDA meeting of 22 October 2020. That meeting occurred prior to their Emergency Use Authorization (EUA) of 11 December 2020, where the dangers were ignored. **The EUA allowed Pfizer, hospital administrators, university officials, medical doctors, clinicians, nurses, et al. to inject the modRNA poison under the secretive protections of LIABILITY IMMUNITY.**

Subject : Mrs. Jummai Nache and her Family



Philip and Jummai Nache are from the African country of Nigeria. They moved to the United States and now they tell other Africans who moved here about Jesus.

Subject : **Mrs. Jummai Nache and her Family**

Subject : Mrs. Jummai Nache and her Family



COVID-19 Vaccination Record Card

Please keep this record card, which includes medical information about the vaccines you have received.

Por favor, guarde esta tarjeta de registro, que incluye información médica sobre las vacunas que ha recibido.

Nache (Last Name) Jummai (First Name) P (MI)

03/02/1971 (Date of birth)

Patient number (medical record or IIS record number)

Vaccine	Product Name/Manufacturer Lot Number	Date	Healthcare Professional or Clinic Site
1st Dose COVID-19	COVID-19 Vaccine Mfg: Pfizer BioNTech Lot:EK9231 Exp:4/30/21	1/13/21 (mm/dd/yy)	M Health Fairview Southdale
2nd Dose COVID-19	COVID-19 Vaccine Mfg: Pfizer BioNTech Lot: EL9262 Exp: 5/31/21	2/1/21 (mm/dd/yy)	M Health Fairview Southdale
Other		___/___/___ (mm/dd/yy)	
Other		___/___/___ (mm/dd/yy)	



Reminder! Return for a second dose!

¡Recordatorio! ¡Regrese para la segunda dosis!

Vaccine	Date / Fecha
COVID-19 vaccine Vacuna contra el COVID-19 0800-0900	02/01/21 (mm/dd/yy)
Other Otra	___/___/___ (mm/dd/yy)

Bring this vaccination record to every vaccination or medical visit. Check with your health care provider to make sure you are not missing any doses of routinely recommended vaccines.

For more information about COVID-19 and COVID-19 vaccine, visit **cdc.gov/coronavirus/2019-ncov/index.html**.

You can report possible adverse reactions following COVID-19 vaccination to the Vaccine Adverse Event Reporting System (VAERS) at **vaers.hhs.gov**.

Lleve este registro de vacunación a cada cita médica o de vacunación. Consulte con su proveedor de atención médica para asegurarse de que no le falte ninguna dosis de las vacunas recomendadas.

Para obtener más información sobre el COVID-19 y la vacuna contra el COVID-19, visite **espanol.cdc.gov/coronavirus/2019-ncov/index.html**.

Puede notificar las posibles reacciones adversas después de la vacunación contra el COVID-19 al Sistema de Notificación de Reacciones Adversas a las Vacunas (VAERS) en **vaers.hhs.gov**.

MLS-319813_1

Subject : **Mrs. Jummai Nache and her Family**

Subject : Mrs. Jummai Nache and her Family

Subject : Mrs. Jummai Nache and her Family





Subject : **Mrs. Jummai Nache and her Family**





Subject : Mrs. Jummai Nache and her Family





Subject : Mrs. Jummai Nache and her Family

Subject : Mrs. Jummai Nache and her Family





Subject : Mrs. Jummai Nache and her Family



Subject : **Mrs. Jummai Nache and her Family**

Mrs. Jummai Nache and devoted husband Philip; learning how to walk stairs on prosthetic limbs. Amputation of her limbs **caused by modRNA injection mandated by her former employer**, the University of Minnesota (UMinn).

A non-smoker, a non-drinker, a *"model of health"* **prior** to Pfizer needle; amputations in pictorial review above caused by modRNA-induced venous and arterial thromboembolism; not merely foreseeable but a known *"mRNA"* danger as discussed in-detail at the secret FDA meeting of 22 October 2020, which occurred **prior** to their Emergency Use Authorization (EUA) on 11 December 2020. The EUA allowed Pfizer, hospital administrators, university officials, medical doctors, clinicians, nurses, et al. to inject the modRNA poison under the secretive protections of **LIABILITY IMMUNITY.**

BOSTON MEDICAL CENTER
EXCEPTIONAL CARE. WITHOUT EXCEPTION.

BU Boston University School of Medicine

Department of Pediatrics
Section of Pediatric Infectious Diseases
Boston Medical Center
670 Albany Street, 6th floor
Boston, MA 02118

March 31, 2021

Lauren Fontana, DO
Infectious Diseases and Internal Medicine
University of Minnesota
420 Delaware Street SE Mayo D-416
Minneapolis, MN 55455

Dear Dr. Fontana:

On behalf of the Clinical Immunization Safety Office (CISA) Project, thank you for the opportunity to review the case of your 49-year-old female patient who was diagnosed with MIS-A following receipt of 2 doses of the Pfizer COVID-19 vaccine. CISA was asked to review the case to assess whether receipt of Pfizer COVID-19 vaccine might have caused or contributed to the adverse event following immunization (AEFI), and to provide guidance regarding future vaccinations, if needed.

CISA is a national research network that provides healthcare providers with expert opinions on adverse events following immunizations as part of the mission of the Centers for Disease Control and Prevention (CDC). This case was reviewed on March 10, 2021 by the CISA Clinical Consultation Case Review Working Group, which includes vaccine safety experts as well as subject matters experts (SME) in neurology, infectious diseases, and allergy/immunology.

The following questions were posed:

1. Is the diagnosis correct?
2. Did the vaccine(s) cause or contribute to the AEFI?
3. What is CISA guidance regarding future vaccines for this patient?
    a. Different formulation?
    b. Vaccine spacing?
4. Is any additional testing warranted?
5. When to schedule follow-up?

CISA vaccine safety and other SMEs reviewed available evidence, including the patient's medical and family history, vaccine safety literature, Vaccine Adverse Event Reporting Systems (VAERS) search results, and package insert information on the Pfizer COVID-19 vaccine. We agreed that the patient met the CDC internal case definition for MIS-A.

Assessment of whether the diagnosis was causally related to the receipt of the Pfizer COVID-19 vaccine was made using the causality algorithm (see diagram and reference below). The SMEs noted that no cases of MIS-A have been associated solely with COVID vaccine (that we know of); all patients to date had some evidence of prior COVID infection. Your patient, too, had evidence of natural disease from SARS CoV-2 infection as documented by a positive nucleocapsid protein antibody on 2/16/21. We are therefore unable to conclude that vaccine caused this case of MIS-A and are unable at this time to assess whether the vaccine may have contributed to this condition. Continued surveillance of similar cases will be important to be able to learn more about this in the future.

The SMEs agreed that currently, the patient does not need another dose of COVID 19 vaccine as she has already received 2 doses. However, if a booster dose should become standard of care, we will need to await further data to help inform that decision at that time.

It is recommended that the patient receive all routine vaccines as necessary and indicated.

No further testing is indicated at this time. However, there is a patient serum sample in storage. The team would recommend hanging on to that sample, as there might be additional testing opportunities in the future that would be helpful for this patient.

The team recommended follow up as needed post discharge.

We hope that we have fully addressed your questions and concerns. Please feel free to contact us if you have any further questions or need to consult us in the future. We have included a link to a survey to evaluate the CISA consultation process in the body of the email accompanying this letter. An additional patient follow-up survey will be sent within the next six months to assess whether the patient has received additional vaccines and how she tolerated them.

Thank you for contacting CISA; we wish your patient a continued recovery.

Sincerely,

Elizabeth D. Barnett, MD
Professor of Pediatrics
Boston University School of Medicine
Section Chief, Pediatric Infectious Diseases
Department of Pediatrics
Boston Medical Center

Stephen I. Pelton, MD
Professor of Pediatrics and Epidemiology
Boston University School of Medicine & Public Health
Pediatric Infectious Diseases
Department of Pediatrics
Boston Medical Center

Disclaimer:

The findings and conclusions in this report are those of the subject matter experts and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Advice from CDC and CISA experts is meant to assist in decision-making rather than provide direct patient management. Patient management decisions are the responsibility of the treating healthcare provider.